Jesse Kwoh
Ionis Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Amyloidosis: Diagnosis, Treatment, Outcomes, Parathyroid Disorders and Treatments, Hepatitis C virus research, Cellular transport and secretion, Influenza Virus Research Studies
Most-Cited Works
- → Early data on long‐term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2‐year update from the open‐label extension of the NEURO‐TTR trial(2020)71 cited
- → Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin Amyloidosis(2023)36 cited
- → 312 Treatment of chronic hepatitis C with ISIS 14803, an antisense inhibitor of HCV, given for 12 weeks(2003)15 cited
- → SAFETY OF INOTERSEN TREATMENT IN PATIENTS WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY(2019)7 cited
- → Long-Term Update from the Open-Label Extension of the NEURO-TTR Study in Patients with Hereditary Transthyretin Amyloidosis(2018)4 cited
- → Phase I trial and pharmacokinetic study of ISIS 5132 combined with carboplatin and paclitaxel for advanced non-small cell lung cancer(2000)3 cited
- → Lack of Pharmacokinetic Drug–Drug Interactions Between Bepirovirsen and Nucleos(t)ide Analogs(2025)3 cited
- → Inotersen Improves Quality of Life and Neuropathy in Patients with Hereditary Transthyretin (HATTR) Amyloidosis with Polyneuropathy: Results of the Phase 3 Study Neuro-TTR(2018)2 cited
- → Estimating Meaningful Differences in Measures of Neuropathic Impairment, Health‐Related Quality of Life, and Nutritional Status in Patients With Hereditary Transthyretin Amyloidosis(2024)2 cited
- → Open Label Extension of the Phase 3 Study NEURO-TTR to Assess the Long-term Efficacy and Safety of Inotersen in Patients With Hereditary Transthyretin Amyloidosis (P1.324)(2018)2 cited